Enveric Biosciences Inc. (ENVB) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, ENVB scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 4 / 20. The rating reflects ROIC of -35% and an FCF yield of 0%. Investor implication: the business is not currently generating returns on invested capital or free cash flow, so value depends on future outcomes not visible in reported cash flows.
• Whale 13F Flow: 6 / 20. The rating references institutional accumulation and options positioning. Investor implication: institutional signals are weak relative to the scoring range; the source data does not provide the underlying 13F detail.
• Insider Conviction: 5 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. Investor implication: insider and congressional signals score low, which provides limited evidence of management or external conviction.
• Macro Regime Fit: 9 / 20. The rating reflects a beta of 1.0 and sector sensitivity. Investor implication: market-sensitivity exposure is average, so the stock is not offering a macro-regime advantage on this measure.
• Forensic Balance Sheet: 10 / 20. The rating reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. Investor implication: the balance sheet screens as mixed-to-weak, with a Piotroski score in the lower range and no clear strength offsetting the cash-flow deficit.

Taken together, the pillar scores point to weakness in cash generation, insider conviction, and forensic balance-sheet quality. Any upside case rests on factors outside the scored fundamentals, and the market capitalization of $6.5M and a share price of 1.46 against a 52-week range of $1.17 - $13.25 indicate a steep decline over the period. Valuation multiples such as P/E are not available in source data, which limits direct valuation tradeoff analysis.

Per the SEC financials, reported revenue is $0.0M in each period shown, and operating income is negative in all three years. Gross, operating, and net margins are each 0% per the market data. ROIC is -35% per the market data, and the Altman Z-Score of 2.5 and Piotroski F-Score of 3/9 are cited in the Roarable RQD rating. Debt/Equity is 0.5 per the Roarable RQD rating, while cash and debt balances are N/A in the SEC financials.

Per the recent news wire, the headlines include: a report on favorable preclinical results for a non-hallucinogenic psychiatric candidate; a report on positive results from IND-enabling ADMET studies; a securities-fraud lawsuit headline referencing a stock decline at another issuer ("Ensign"), which is not clearly tied to ENVB in the source; a patent-related headline referencing a different company (Microbot Medical); and a seasonal chart headline referencing Acurx Pharmaceuticals. Each item carries a YELLOW light and MARKET WIRE impact label. Watch items include the reliance on preclinical milestones and the presence of unrelated-company headlines in the feed, which limits direct attribution. Per the Butterfly Supply-Chain Graph, the supply chain is "NONE" with no butterfly links and no proprietary signals.

• What are the reported cash, debt, and EPS figures, since the SEC financials show N/A for each?
• Why do net income figures ($12.1M, $9.6M, $17.5M) diverge sharply from negative operating income and revenue of $0.0M?
• What is the status and timing of the preclinical and IND-enabling programs referenced in the news wire?
• What are the institutional (13F) and insider (Form 4) holdings, given that the holders section is empty?
• How does the Altman Z-Score of 2.5 reconcile with the Piotroski F-Score of 3/9 and the FCF deficit?